Durable progression-free survival benefit in early responders to elotuzumab plus lenalidomide and dexamethasone (ELd): analysis of ELOQUENT-2 4-year data in relapsed/refractory (RR) multiple myeloma (MM)

被引：0
|
作者：
Scheid, C. [1 ]
Roellig, C. [2 ]
Weisel, K. [3 ]
Salwender, H-J [4 ]
Gramatzki, M. [5 ]
Edmaier-Schroeger, K. [6 ]
Sy, O. [7 ]
Goldschmidt, H. [8 ]
机构：
[1] Univ Klinikum Koln, Cologne, Germany
[2] Univ Dresden, Dresden, Germany
[3] Univ Tubingen, Tubingen, Germany
[4] Asklepios Klin Hamburg, Hamburg, Germany
[5] Univ Schleswig Holstein, Kiel, Germany
[6] Bristol Myers Squibb, Munich, Germany
[7] Bristol Myers Squibb, Princeton, NJ USA
[8] Heidelberg Univ, Natl Ctr Tumor Dis, Heidelberg, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P571
引用
收藏
页码：189 / 189
页数：1
相关论文
共 50 条
  • [21] ASSOCIATION BETWEEN PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS WITH RELAPSED/REFRACTORY (RR) MULTIPLE MYELOMA (MM)
    Mastikhina, L.
    Cope, S.
    Marshall, T.
    Maciel, D.
    Mojebi, A.
    Karampampa, K.
    Dhanda, D.
    VALUE IN HEALTH, 2023, 26 (12) : S30 - S31
  • [22] ELOQUENT-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone (ELd) vs Lenalidomide/Dexamethasone (Ld) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)-3-Year Safety and Efficacy Follow-up
    Dimopoulos, M.
    Lonial, S.
    White, D.
    Moreau, P.
    Palumbo, A.
    San Miguel, J.
    Shpilberg, O.
    Anderson, K.
    Grosicki, S.
    Spicka, I.
    Walter-Croneck, A.
    Magen-Nativ, H.
    Mateos, M. -V
    Belch, A.
    Reece, D.
    Beksac, M.
    Bleickardt, E.
    Poulart, V.
    Katz, J.
    Singhal, A. K.
    Richardson, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 122 - 123
  • [23] CARFILZOMIB AND LENALIDOMIDE AND DEXAMETHASONE VS LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: TEMPORARY ANALYSIS OF RESPONSE TO THE HAZARD RATIO FOR PROGRESSION-FREE SURVIVAL
    Maria Victoria, Mateos Manteca
    Meletios, Dimopoulos A.
    Keith, Stewart A.
    Michael, Wang
    Vladimir, Maisnar
    Jiri, Minarik
    William, Bensinger, I
    Dina, Ben-Yehuda
    Vishal, Kukreti
    Mihaela, Obreja
    Sanjay, Aggarwal
    Philippe, Moreau
    Antonio, Palumbo
    HAEMATOLOGICA, 2016, 101 : 27 - 27
  • [24] Long-time progression-free survival in relapsed, refractory multiple myeloma with the oral ixazomib-lenalidomide-dexamethasone regime
    Hardi, Apor
    Varga, Gergely
    Nagy, Zsolt
    Kosztolanyi, Szabolcs
    Varoczy, Laszlo
    Plander, Mark
    Schneider, Tamas
    Demeter, Judit
    Alizadeh, Hussain
    Illes, Arpad
    Masszi, Tamas
    Mikala, Gabor
    ORVOSI HETILAP, 2021, 162 (36) : 1451 - 1458
  • [25] ELOQUENT-3 study: elotuzumab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma - final analysis of overall survival (OS)
    Raab, M. S.
    Dimopoulos, M.
    Dytfeld, D.
    Grosicki, S.
    Moreau, P.
    Takezako, N.
    Hori, M.
    Leleu, X.
    LeBlanc, R.
    Suzuki, K.
    Richardson, P. G.
    Popa McKiver, M.
    Jou, Y. -M.
    Yao, D.
    Das, P.
    San-Miguel, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 87 - 87
  • [26] CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE VS LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: ANALYSIS OF RESPONSE AND PROGRESSION-FREE SURVIVAL HAZARD RATIO OVER TIME
    Dimopoulos, M. A.
    Stewart, A. K.
    Wang, M.
    Maisnar, V.
    Minarik, J.
    Bensinger, W. I.
    Mateos, M. V.
    Ben-Yehuda, D.
    Kukreti, V.
    Obreja, M.
    Aggarwal, S.
    Moreau, P.
    Palumbo, A.
    HAEMATOLOGICA, 2016, 101 : 83 - 83
  • [27] ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
    Lonial, Sagar
    Dimopoulos, Meletios A.
    Palumbo, Antonio
    White, Darrell
    Grosicki, Sebastian
    Spicka, Ivan
    Walter-Croneck, Adam
    Moreau, Philippe
    Mateos, Maria-Victoria
    Magen-Nativ, Hila
    Belch, Andrew
    Reece, Donna Ellen
    Beksac, Meral
    Taniwaki, Masafumi
    Roellig, Christoph
    Singhal, Anil K.
    Katz, Jessica
    Bleickardt, Eric W.
    Poulart, Valerie
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [28] Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma-3-Year Safety and Efficacy Follow-up
    Dimopoulos, Meletios A.
    Lonial, Sagar
    White, Darrell
    Moreau, Philippe
    Palumbo, Antonio
    San Miguel, Jesus
    Shpilberg, Ofer
    Anderson, Kenneth C.
    Grosicki, Sebastian
    Spicka, Ivan
    Walter-Croneck, Adam
    Magen-Nativ, Hila
    Mateos, Maria-Victoria
    Belch, Andrew
    Reece, Donna
    Beksac, Meral
    Bleickhardt, Eric
    Poulart, Valerie
    Katz, Jessica
    Singhal, Anil K.
    Richardson, Paul G.
    BLOOD, 2015, 126 (23)
  • [29] Cost per median month of progression-free survival for daratumumab plus bortezomib and dexamethasone compared with carfilzomib plus dexamethasone in relapsed/refractory multiple myeloma.
    Maiese, Eric
    Graham, Christopher N.
    Hawe, Emma
    Le Moine, Jean-Gabriel
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [30] Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial
    Dimopoulos, Meletios A.
    Dytfeld, Dominik
    Grosicki, Sebastian
    Moreau, Philippe
    Takezako, Naoki
    Hori, Mitsuo
    Leleu, Xavier
    LeBlanc, Richard
    Suzuki, Kenshi
    Raab, Marc S.
    Richardson, Paul G.
    McKiver, Mihaela Popa
    Jou, Ying-Ming
    Yao, David
    Das, Prianka
    San-Miguel, Jesus
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (03) : 568 - +
12345